Quick Answer
Mereo BioPharma Group plc reported R&D Expense of $17.77 million for fiscal year 2025.
Mereo BioPharma Group plc R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $17.77M | -15.1% |
| 2024 | $20.93M | +20.2% |
| 2023 | $17.42M | -40.9% |
| 2022 | $29.46M | +25.1% |
| 2021 | $23.56M | +44.1% |
| 2020 | $16.35M | -30.8% |
| 2019 | $23.61M | +4.0% |
| 2018 | $22.70M | -34.4% |
| 2017 | $34.61M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $4.27M | +34.7% | -20.5% |
| June 30, 2025 | $5.37M | +8.6% | +36.7% |
| March 31, 2025 | $3.93M | -1.6% | +24.0% |
| September 30, 2024 | $3.17M | -11.8% | -35.9% |
| June 30, 2024 | $4.95M | +33.2% | +23.8% |
| March 31, 2024 | $3.99M | -24.7% | +11.1% |
| September 30, 2023 | $3.59M | — | -3.2% |
| June 30, 2023 | $3.71M | — | -30.1% |
- Mereo BioPharma Group plc showed a decrease of -15.1% in R&D Expense compared to the prior fiscal year.
- Over the 2017–2025 period, Mereo BioPharma Group plc’s r&d expense has declined by 48.7% (from $34.61 million to $17.77 million).
- The most recent figure is from Mereo BioPharma Group plc’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 19, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: